Treatment of visceral leishmaniasis in children with liposomal amphotericin B

被引：53

作者：

diMartino, L

Davidson, RN

Giacchino, R

Scotti, S

Raimondi, F

Castagnola, E

Tasso, L

Cascio, A

Gradoni, L

Gramiccia, M

PettoelloMantovani, M

Bryceson, ADM

机构：

[1] YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT PEDIAT, BRONX, NY 10461 USA

[2] IST GIANNINA GASLINI, DEPT PEDIAT, I-16148 GENOA, ITALY

[3] UNIV NAPLES FEDERICO II, DEPT PEDIAT, NAPLES, ITALY

[4] CHILDRENS HOSP, DEPT PEDIAT, PALERMO, ITALY

[5] IST SUPER SANITA, PARASITOL LAB, I-00161 ROME, ITALY

[6] ST MARYS HOSP, SCH MED, DEPT INFECT & TROP DIS, HARROW, MIDDX, ENGLAND

[7] HOSP TROP DIS, LONDON NW1 0PE, ENGLAND

[8] UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, SCH MED, LONDON SW7 2AZ, ENGLAND

来源：

JOURNAL OF PEDIATRICS | 1997年 / 131卷 / 02期

关键词：

D O I：

10.1016/S0022-3476(97)70165-3

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

We used liposomal amphotericin B as first-choice treatment of visceral leishmaniasis in 106 immunocompetent children who acquired the infection in a temperate region of southern Europe (Italy) where Leishmania infantum visceral leishmaniasis is endemic. The aim of the study was to identify the minimum total dose of liposomal amphotericin B needed to cue the infection in children and reduce the period of hospitalization. We conclude that the optimal regimen in immunocompetent children with L. infantum visceral leishmaniasis to be a total dose of 18 mg/kg of liposomal amphotericin B (3 mg/kg per day for 5 days, followed by 3 mg/kg administered as an outpatient regimen on day 10).

引用

页码：271 / 277

页数：7

共 50 条

[1] Treatment of visceral leishmaniasis with liposomal amphotericin B
不详
[J]. HOSPITAL MEDICINE, 2001, 62 (09): : 577 - 577
[2] Liposomal amphotericin B for the treatment of visceral leishmaniasis
Bern, Caryn
Adler-Moore, Jill
Berenguer, Juan
Boelaert, Marleen
den Boer, Margriet
Davidson, Robert N.
Figueras, Concepcion
Gradoni, Luigi
Kafetzis, Dimitris A.
Ritmeijer, Koert
Rosenthal, Eric
Royce, Catherine
Russo, Rosario
Sundar, Shyam
Alvar, Jorge
[J]. CLINICAL INFECTIOUS DISEASES, 2006, 43 (07) : 917 - 924
[3] LIPOSOMAL AMPHOTERICIN-B IN THE TREATMENT OF VISCERAL LEISHMANIASIS
CROFT, SL
DAVIDSON, RN
THORNTON, EA
[J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1991, 28 : 111 - 118
[4] VISCERAL LEISHMANIASIS FOLLOWING TREATMENT WITH LIPOSOMAL AMPHOTERICIN-B
MCBRIDE, M
LINNEY, M
CLAYDON, EJ
WEBER, J
[J]. CLINICAL INFECTIOUS DISEASES, 1994, 19 (02) : 362 - 362
[5] Early efficacy of liposomal amphotericin B in the treatment of visceral leishmaniasis
Castagnola, E
Davidson, RN
Fiore, P
Tasso, L
Rossi, G
Mangraviti, S
DiMartino, L
Scotti, S
Cascio, A
Pempinello, R
Gradoni, L
Giacchino, R
[J]. TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 1996, 90 (03) : 317 - 318
[6] Liposomal amphotericin B as treatment for visceral leishmaniasis in Europe, 2009
Rosenthal, E.
Delaunay, P.
Jeandel, P. -Y.
Haas, H.
Pomares-Estran, C.
Marty, P.
[J]. MEDECINE ET MALADIES INFECTIEUSES, 2009, 39 (10): : 741 - 744
[7] Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompetent patients
Minodier, P
Retornaz, K
Horelt, A
Garnier, JM
[J]. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2003, 17 (02) : 183 - 188
[8] Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompromised patients
Vigna, E.
De Vivo, A.
Gentile, M.
Morelli, R.
Lucia, E.
Mazzone, C.
Recchia, A. G.
Vianelli, N.
Morabito, F.
[J]. TRANSPLANT INFECTIOUS DISEASE, 2010, 12 (05) : 428 - 431
[9] Visceral leishmaniasis treated with liposomal amphotericin B
Catania, S
Aiassa, C
Tzahtzoglou, S
Catania, N
Tucciarone, L
Antimi, A
Ragni, G
Clerico, A
[J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1999, 18 (01) : 73 - 75
[10] Liposomal amphotericin B to treat visceral leishmaniasis
Monge-Maillo, Begona
Lopez-Velez, Rogelio
[J]. REVISTA IBEROAMERICANA DE MICOLOGIA, 2021, 38 (02): : 101 - 104

← 1 2 3 4 5 →